$CYTH
Cyclo Therapeutics, Inc.

2020 Q1 Form 10-Q Financial Statement

#000143774920011000 Filed on May 15, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1 2018 Q4
Revenue $325.7K $220.8K $240.0K
YoY Change 47.51% 11.49% 41.18%
Cost Of Revenue $30.00K $20.55K $20.00K
YoY Change 45.99% -13.19% 0.0%
Gross Profit $300.0K $200.3K $220.0K
YoY Change 49.79% 14.84% 46.67%
Gross Profit Margin 92.1% 90.69% 91.67%
Selling, General & Admin $880.0K $760.0K $610.0K
YoY Change 15.79% 31.03% -17.57%
% of Gross Profit 293.33% 379.48% 277.27%
Research & Development $2.060M $1.343M $970.0K
YoY Change 53.39% 228.15% 24.36%
% of Gross Profit 686.54% 670.46% 440.91%
Depreciation & Amortization $3.118K $1.484K $0.00
YoY Change 110.11% -40.64%
% of Gross Profit 1.04% 0.74% 0.0%
Operating Expenses $2.060M $1.343M $1.580M
YoY Change 53.39% 228.15% 3.27%
Operating Profit -$2.642M -$1.908M -$1.360M
YoY Change 38.49% 134.26% -1.45%
Interest Expense $10.00K $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.634M -$1.904M -$1.370M
YoY Change 38.33% 134.23% -0.72%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.634M -$1.904M -$1.370M
YoY Change 38.33% 134.23% -0.72%
Net Earnings / Revenue -808.63% -862.29% -570.83%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.174M -$2.088M -$1.557M
COMMON SHARES
Basic Shares Outstanding 121.7M 91.26M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q1 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $930.0K $1.120M $2.220M
YoY Change -16.96% 83.61% 74.8%
Cash & Equivalents $933.5K $1.115M $2.217M
Short-Term Investments
Other Short-Term Assets $730.0K $46.90K $18.19K
YoY Change 1456.47% -27.96% -70.11%
Inventory $228.8K $413.3K $416.5K
Prepaid Expenses
Receivables $168.8K $74.80K $80.04K
Other Receivables $40.00K $40.00K $40.00K
Total Short-Term Assets $2.097M $1.688M $2.770M
YoY Change 24.28% 39.27% 46.09%
LONG-TERM ASSETS
Property, Plant & Equipment $61.06K $18.41K $18.57K
YoY Change 231.62% -25.97% -27.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $15.00K
YoY Change
Total Long-Term Assets $188.8K $217.6K $148.2K
YoY Change -13.25% 15.11% -23.13%
TOTAL ASSETS
Total Short-Term Assets $2.097M $1.688M $2.770M
Total Long-Term Assets $188.8K $217.6K $148.2K
Total Assets $2.286M $1.905M $2.918M
YoY Change 19.99% 36.01% 39.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.940M $2.620M $1.930M
YoY Change 50.38% 164.65% 105.32%
Accrued Expenses $20.00K $10.00K
YoY Change 100.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.952M $2.637M $1.925M
YoY Change 49.9% 146.87% 104.16%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $30.00K $50.00K
YoY Change -40.0%
Total Long-Term Liabilities $30.00K $50.00K $0.00
YoY Change -40.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.952M $2.637M $1.925M
Total Long-Term Liabilities $30.00K $50.00K $0.00
Total Liabilities $3.980M $2.690M $1.930M
YoY Change 47.96% 151.4% 105.32%
SHAREHOLDERS EQUITY
Retained Earnings -$27.75M -$19.49M -$17.59M
YoY Change 42.39% 37.79% 31.91%
Common Stock $12.16K $9.075K $9.075K
YoY Change 33.94% 24.33% 24.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.698M -$781.6K $992.5K
YoY Change
Total Liabilities & Shareholders Equity $2.286M $1.905M $2.918M
YoY Change 19.99% 36.01% 39.7%

Cashflow Statement

Concept 2020 Q1 2019 Q1 2018 Q4
OPERATING ACTIVITIES
Net Income -$2.634M -$1.904M -$1.370M
YoY Change 38.33% 134.23% -0.72%
Depreciation, Depletion And Amortization $3.118K $1.484K $0.00
YoY Change 110.11% -40.64%
Cash From Operating Activities -$1.809M -$1.225M -$1.060M
YoY Change 47.67% 66.09% 8.16%
INVESTING ACTIVITIES
Capital Expenditures $50.63K $1.324K $0.00
YoY Change 3723.79% -18.97%
Acquisitions
YoY Change
Other Investing Activities $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0%
Cash From Investing Activities -$41.01K $7.892K $0.00
YoY Change -619.67% 507.08% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 115.1K 2.140M
YoY Change 53.45% 137.78%
NET CHANGE
Cash From Operating Activities -1.809M -1.225M -1.060M
Cash From Investing Activities -41.01K 7.892K 0.000
Cash From Financing Activities 115.1K 2.140M
Net Change In Cash -1.850M -1.102M 1.080M
YoY Change 67.86% 66.65% -1642.86%
FREE CASH FLOW
Cash From Operating Activities -$1.809M -$1.225M -$1.060M
Capital Expenditures $50.63K $1.324K $0.00
Free Cash Flow -$1.860M -$1.227M -$1.060M
YoY Change 51.63% 65.9% 8.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 ctdh Cost Of Goods And Services Sold Excluding Direct And Indirect Overhead And Handling Costs
CostOfGoodsAndServicesSoldExcludingDirectAndIndirectOverheadAndHandlingCosts
26433
CY2019Q1 ctdh Cost Of Goods And Services Sold Excluding Direct And Indirect Overhead And Handling Costs
CostOfGoodsAndServicesSoldExcludingDirectAndIndirectOverheadAndHandlingCosts
20550
CY2019Q1 ctdh Equity Impact Of Cash Received From Stock Subscription
EquityImpactOfCashReceivedFromStockSubscription
130062
CY2020Q1 ctdh Freight And Shipping
FreightAndShipping
1863
CY2019Q1 ctdh Freight And Shipping
FreightAndShipping
1434
CY2020Q1 ctdh Increase Decrease Prepaid Clinical Expenses
IncreaseDecreasePrepaidClinicalExpenses
-59096
CY2019Q1 ctdh Increase Decrease Prepaid Clinical Expenses
IncreaseDecreasePrepaidClinicalExpenses
CY2016Q1 ctdh Mortgage Loans On Real Estate Monthly Payment
MortgageLoansOnRealEstateMonthlyPayment
3653
CY2020Q1 ctdh Number Of Major Customers
NumberOfMajorCustomers
3
CY2019Q1 ctdh Number Of Major Customers
NumberOfMajorCustomers
3
CY2020Q1 ctdh Operating Lease Right Of Usse Asset Amortization
OperatingLeaseRightOfUsseAssetAmortization
21256
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000922247
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
Cyclo Therapeutics, Inc.
CY2020Q1 ctdh Prepaid Expenses Current Excluding Prepaid Insurance
PrepaidExpensesCurrentExcludingPrepaidInsurance
553065
CY2019Q4 ctdh Prepaid Expenses Current Excluding Prepaid Insurance
PrepaidExpensesCurrentExcludingPrepaidInsurance
612161
CY2020Q1 ctdh Proceeds From Collection Of Stock Subscription
ProceedsFromCollectionOfStockSubscription
CY2019Q1 ctdh Proceeds From Collection Of Stock Subscription
ProceedsFromCollectionOfStockSubscription
130062
CY2020Q1 ctdh Repairs And Maintenance
RepairsAndMaintenance
1802
CY2019Q1 ctdh Repairs And Maintenance
RepairsAndMaintenance
1684
CY2020Q1 ctdh Sharebased Compensation Employees
SharebasedCompensationEmployees
2470
CY2019Q1 ctdh Sharebased Compensation Employees
SharebasedCompensationEmployees
7300
CY2020Q1 ctdh Sharebased Compensation Nonemployees
SharebasedCompensationNonemployees
4750
CY2019Q1 ctdh Sharebased Compensation Nonemployees
SharebasedCompensationNonemployees
24090
CY2020Q1 ctdh Working Capital
WorkingCapital
1855000
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q1 dei Security12g Title
Security12gTitle
Common Stock, par value $0.0001
CY2016Q1 srt Mortgage Loans On Real Estate Face Amount Of Mortgages
MortgageLoansOnRealEstateFaceAmountOfMortgages
265000
CY2016Q1 srt Mortgage Loans On Real Estate Interest Rate
MortgageLoansOnRealEstateInterestRate
0.0425
CY2020Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3935585
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3124735
CY2020Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
168823
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
143429
CY2020Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
26044060
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
26044060
CY2020Q1 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
824742
CY2019Q1 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
678933
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7220
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31390
CY2020Q1 us-gaap Assets
Assets
2286061
CY2019Q4 us-gaap Assets
Assets
4113228
CY2020Q1 us-gaap Assets Current
AssetsCurrent
2097259
CY2019Q4 us-gaap Assets Current
AssetsCurrent
3958069
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2020Q1 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
CY2019Q1 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
64231
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
933457
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2783719
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2217412
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1115133
CY2020Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1850262
CY2019Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1102279
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
121564990
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
121564990
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
121564990
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
121564990
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
12155
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
12155
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
2967774
CY2019Q1 us-gaap Costs And Expenses
CostsAndExpenses
2128616
CY2020Q1 us-gaap Depreciation
Depreciation
3118
CY2019Q1 us-gaap Depreciation
Depreciation
1484
CY2020Q1 us-gaap Depreciation Nonproduction
DepreciationNonproduction
3118
CY2019Q1 us-gaap Depreciation Nonproduction
DepreciationNonproduction
1484
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2019Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
28716
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2633992
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1904166
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2020Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
CY2019Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
803630
CY2019Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
665789
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
25394
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5248
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-13859
CY2019Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-3278
CY2020Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
9615
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1904166
CY2020Q1 us-gaap Increase Decrease In Prepaid Insurance
IncreaseDecreaseInPrepaidInsurance
37013
CY2019Q1 us-gaap Increase Decrease In Prepaid Insurance
IncreaseDecreaseInPrepaidInsurance
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
CY2019Q1 us-gaap Interest Paid Net
InterestPaidNet
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-226
CY2019Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-460
CY2020Q1 us-gaap Inventory Net
InventoryNet
228771
CY2019Q4 us-gaap Inventory Net
InventoryNet
242630
CY2020Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
52900
CY2019Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
52900
CY2020Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
8048
CY2019Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
3624
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2286061
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4113228
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3952301
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3141120
CY2020Q1 us-gaap Long Term Accounts Notes And Loans Receivable Net Noncurrent
LongTermAccountsNotesAndLoansReceivableNetNoncurrent
80981
CY2019Q4 us-gaap Long Term Accounts Notes And Loans Receivable Net Noncurrent
LongTermAccountsNotesAndLoansReceivableNetNoncurrent
90596
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
115062
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-41012
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7892
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1809250
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1225233
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2633992
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-7533000
CY2020Q1 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
7349
CY2019Q1 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
33085
CY2020Q1 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
39061
CY2019Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
39061
CY2020Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2642040
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1907790
CY2020Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
4251
CY2019Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
4251
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
16716
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
16385
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
31770
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
36126
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
46766
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
51017
CY2020Q1 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
178362
CY2019Q1 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
102642
CY2020Q1 us-gaap Payments For Proceeds From Loans Receivable
PaymentsForProceedsFromLoansReceivable
-9615
CY2019Q1 us-gaap Payments For Proceeds From Loans Receivable
PaymentsForProceedsFromLoansReceivable
-9216
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
50627
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1324
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q1 us-gaap Prepaid Insurance
PrepaidInsurance
174082
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
137069
CY2020Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
CY2019Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-15000
CY2016Q1 us-gaap Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
10000
CY2020Q1 us-gaap Professional Fees
ProfessionalFees
219536
CY2019Q1 us-gaap Professional Fees
ProfessionalFees
214975
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
61055
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13546
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2059606
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1342763
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-27754225
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25120233
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
325734
CY2019Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
220826
CY2020Q1 us-gaap Salaries And Wages
SalariesAndWages
469705
CY2019Q1 us-gaap Salaries And Wages
SalariesAndWages
409999
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-1698010
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
935982
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
992524
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-781580
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">(r) USE OF ESTIMATES&#x2013;&#x2013;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes, including contingencies. The Company&#x2019;s most significant estimate relates to inventory obsolescence. Although management bases its estimates on historical experience and assumptions that are believed to be reasonable under the circumstances, actual results could significantly differ from these estimates.<div style="display: inline; font-weight: bold;"> </div></div></div></div></div></div>
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
121086101
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
90759324

Files In Submission

Name View Source Status
0001437749-20-011000-index-headers.html Edgar Link pending
0001437749-20-011000-index.html Edgar Link pending
0001437749-20-011000.txt Edgar Link pending
0001437749-20-011000-xbrl.zip Edgar Link pending
ctdh-20200331.xml Edgar Link completed
ctdh-20200331.xsd Edgar Link pending
ctdh-20200331_cal.xml Edgar Link unprocessable
ctdh-20200331_def.xml Edgar Link unprocessable
ctdh-20200331_lab.xml Edgar Link unprocessable
ctdh-20200331_pre.xml Edgar Link unprocessable
ctdh20200331_10q.htm Edgar Link pending
ex_186174.htm Edgar Link pending
ex_186175.htm Edgar Link pending
ex_186176.htm Edgar Link pending
ex_186177.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending